The partners are planning to conduct meta-analyses of shared exome datasets from patients with inherited neurological disorders.
Opko subsidiary Bio-Reference Laboratories is retiring GeneTests.org next month given the availability of the NIH-backed Genetic Testing Registry.
The alliance will combine the two firms' technologies and know-how to provide doctors with insights into patients' health status.
Under today's deal, all of UC Health's medical centers will work with GeneDx and have access to more than 400 of the firm's tests for rare hereditary disorders.
The company awaits a decision from Medicare contractor Novitas, which issued a positive LCD in 2016 but withdrew it in response to a negative LCD from Palmetto.
Around 16,000 4Kscore prostate cancer tests were performed in Q3, which is a 365 percent increase over Q3 2015.
The company, which is part of Opko Health's BioReference Laboratories, recently hired a new managing director, who plans to expand the firm's market and testing portfolio.
Experts at CAP16 said most practicing pathologists operate within specialties and rarely cross the divide into other test disciplines, which thwarts optimal patient care.
The revenue surge was largely due to revenues from Bio-Reference Laboratories, which Opko acquired in August 2015.
The company's revenues benefitted from the acquisition of Bio-Reference Laboratories this summer, which helped push up diagnostic services revenues.
Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.
The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.
Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.
In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.